Title of Invention	"QUINAZOLINONE LINKED PYRROLO [2,1-C][1,4] BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF"
Abstract	The present invention provides quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of general formula 5 , wherein, R is alkyl group selected from H, Cl, F or CH3 and n=1 to 3 useful for antitumour/anticancer activity. The present invention also provides a process for the preparation of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid general formula 5.

Full Text

FIELD OF THE INVENTION The present invention relates to quinazolinone linked pyrrolo[2,1-c][1,4] benzodiazepine hybrids of general formula 5, useful as potential anti tumour agents and a process for the preparation thereof. Particularly it relates to a process for the preparation of 7-methoxy-8-[n-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl) alkyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one with aliphatic chain length variations for these compounds. The structural formula of these novel quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepines is given below. (Formula Removed) formula 5 wherein, R is an alkyl group selected from H, Cl, F and and n=1 , 2 or 3. BACKGROUND OF THE INEVNTION Pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics are commonly known as anthramycin class of compounds. In the last few years, a growing interest has been shown in the development of new pyrrolo[2,1-c][1,4]benzodiazepines (PBDs). These antibiotics react covalently with DMA to form an N2-guanine adduct that lies within the minor groove of duplex DMA via an acid-labile aminal bond to the electrophilic imine at the N10-C11 position (Kunimoto, S.; Masuda, T.; Kanbayashi, N.; Hamada, M.; Naganawa, H.; Miyamoto, M.; Takeuchi, T.; Unezawa, H. J. Antibiot., 1980, 33, 665.; Kohn, K. W. and Speous, C. L. J. Mol. Biol., 1970, 51, 551.; Hurley, L. H.; Gairpla, C. and Zmijewski, M. Biochem. Biophys. Acta., 1977, 475, 521.; Kaplan, D. J. and Hurley, L. H. Biochemistry, 1981, 20, 7572). The molecules have a right-handed twist, which allows them to follow the curvature of the minor groove of B-form double-stranded DMA spanning three base pairs. A recent development has been the linking of two PBD units through their C-8 positions to give bisfunctional-alkylating agents capable of cross-linking DMA (Thurston, D. E.; Bose, D. S.; Thomson, A. S.; Howard, P. W.; Leoni, A.; Croker, S. J.; Jenkins, T. C.; Neidle, S. and Hurley, L. H. J. Org. Chem. 1996, 61, 8141). (Figure Removed) Recently, PBD dimers have been developed that comprise of two C2-exo-methylene substituted DC-81 subunits tethered through their C-8 position via an inert propanedioxy linker (Gregson, S. J.; Howard, P. W.; Hartely, J. A.; Brooks, N. A.; Adams, L. J.; Jenkins, T. C.; Kelland, L. R. and Thurston, D. E. J. Med. Chem. 2001, 44, 737). Recently, a noncross-linking mixed imine-amide PBD dimers have been synthesized that have significant DMA binding ability and potent antitumour activity (Kamal, A.; Ramesh, G. Laxman, N.; Ramulu, P.; Srinivas, O.; Neelima, K.; Kondapi, A. K.; Srinu, V. B.; Nagarajaram, H. M. J. Med. Chem. 2002, 45, 4679). Naturally occurring pyrrolo[2,1-c][1,4]benzodiazepines belong to a group of antitumour antibiotics derived from Streptomyces species. Recently, there is much impetus for the PBD systems as they can recognize and bind to specific sequence of DMA. Examples of naturally occurring PBDs include anthramycin, DC-81, tomaymycin, sibiromycin and neothramycin. However, the clinical efficacy for these antibiotics is hindered by several limitations, such as poor water solubility, cardiotoxicity, development of drug resistance and metabolic inactivation. OBJECTIVES OF THE INVENTION The main objective of the present invention is to provide novel quinazolinone linked pyrrolo[2,1-c][1,4] benzodiazepine hybrids, useful as antitumour agents. Another objective of this invention is to provide a process for the preparation of novel quinazolinone linked pyrrolo[2,1-c] [1,4]benzodiazepine hybrid of formula 5. (Figure Removed) SUMMARY OF THE INVENTION Accordingly the present invention provides novel quinazolinone linked pyrrolo [2,1-c][1,4]benzodiazepine hybrid of general formula 5, (Figure Removed) wherein, R is an alkyl group selected from H, Cl, F and CH3 and n = 1, 2, 3 or 4. In an embodiment of the present invention the quinazolinone linked pyrrolo [2,1-c][1,4]benzodiazepine hybrid of formula 5 is represented by the group of the following compounds: 7-Methoxy-8-[3-(6-H-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5a); 7 -Methoxy-8-[4-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5b); 7-Methoxy-8-[5-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4]benzodiazepine-5-one (5c); 7-Methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5d); 7 -Methoxy-8-[4-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5e); 7-Methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5f); 7-Methoxy-8-[3-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5g); 7 -Methoxy-8-[4-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5h); 7-Methoxy-8-[5-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5i), 7-Methoxy-8-[3-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one(5j); 7 -Methoxy-8-[4-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5k) and 7-Methoxy-8-[5-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one(5l). In yet another embodiment the structural formula of the representative compounds of quinazolinone linked pyrrolo [2,1-c][1,4]benzodiazepine hybrid of formula 5 are: (Figure Removed) In yet another embodiment quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5, exhibits an in vitro anticancer/antitumour activity against human cancer cell lines selected from the group consisting of lung, cervix, breast, colon, prostate and oral cell lines. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against Colo205 for IC50 is in the range of 8 to 15|am, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against DU145 for IC50 is in the range of 8 to 15|^m, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against DWD for IC50 is in the range of 8 to 10|am, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against HoP62 for IC50 is 5^171, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against HT1080 for IC50 is in the range of 8 to 9^im, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against MCF7 for IC50 is in the range of 8 to 12|im, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against PCS for IC50 is in the range of 7 to 11^m, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against SiHa for IC50 is in the range of 8 to 15(^m, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5 used for in vitro activity against Zr-75-1 for IC50 is in the range of 8 to IS^m, at an exposure period of at least 48 hrs. The present invention further provides a pharmaceutical composition comprising quinazolinone linked pyrrolo[2,1-c][1,4] benzodiazepine hybrid of formula 5, its derivatives, analogues, salts or mixture thereof optionally with pharmaceutically acceptable carriers, adjuvants and additives. In an embodiment of the present invention the quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid used in pharmaceutical composition is represented by a general formula 5, (Figure Removed) Formula 5 wherein, R is alkyl group selected from H, Cl, F and CH3 and n = 1, 2 or 3. The present invention further provides a process for the preparation of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5, (Figure Removed) wherein, R is alkyl group selected from H, Cl, F and CHa and n = 1, 2 or 3, the said process comprising the steps of: a) reacting (2S)-A/-(4-hydroxy-3-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 2 (Figure Removed) with 1 -(n-bromo alkyl)-6-R-4-phenyl-1,2-dihydro-2-quinazolinone of formula 1, wherein R is selected from the group consisting of H, Cl, F and CH3 and n = 1, 2 or 3, in an aprotic water miscible organic solvent, (Figure Removed) in the presence of anhydrous mild inorganic base, under refluxing temperature in an oil bath, for a period of about 48 hrs, followed by the removal of inorganic base by filtration and evaporating the organic solvent to obtain the resultant crude product and purifying it by known method to obtain the desired product of 2S-A/-{4-[3-(6-R-4-phenyl-1,2-dihydro-2-quinazolinone)]alkyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethylthioacetal of formula 3, (Figure Removed) NO2 £H(SEt)2 b) reducing 2S-A/-{4-[3-(6-R-4-phenyl-1,2-dihydro-2-quinazolinone)] alkyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 with anhydrous tin chloride, in an alcohol, under reflux, followed by the evaporation of alcohol and adjusting the pH of the resultant product layer to about 8 by using a base, followed by extraction with ethyl acetate and washing the combined organic phase with brine solution and evaporating the solvent to obtain the desired 2S-A/-{4-[3-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]alkyl]oxy-5-methoxy-2-aminobenzoyl} pyrroli dine -2-carboxaldehyde diethyl thioacetal of formula formula 4, wherein R is selected from the group consisting of H, Cl, F and CH3 and n = 1, 2 or 3, (Figure Removed) c) reacting 2S-A/-{4-[3-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)] alkyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethylthioacetal of formula 4 with mercurous chloride, in a mixture of water and organic solvent, in the presence of mild inorganic, under stirring, at a temperature of about 20-30°C, for a period of 8-12 hrs, followed by the extraction of yellow organic supernatant and washing with sodium bi carbonate and brine, respectively, and evaporating the organic layer, under reduced pressure to obtain the desired product of formula 5. In yet another embodiment the mild inorganic base used in steps (a) & (b) is potassium carbonate. In yet another embodiment the aprotic organic solvent used in step (a) is acetone. In yet another embodiment the organic solvent used in step (c) is acetonitrile. In yet another embodiment the alcohol used in step (b) is selected from methanol and ethanol. In yet another embodiment the compounds of formula 5 obtained are represented by a group of the following compounds: 7-Methoxy-8-[3-(6-H-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)propoxy]-(11 aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one (5a); 7 -Methoxy-8-[4-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5b); 7-Methoxy-8-[5-(6-H-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5c); 7-Methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5d); 7 -Methoxy-8-[4-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5e); 7-Methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5f); 7-Methoxy-8-[3-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5g); 7 -Methoxy-8-[4-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5h); 7-Methoxy-8-[5-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11 aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4]benzodiazepine-5-one (5i), 7-Methoxy-8-[3-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11 aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one (5j); 7 -Methoxy-8-[4-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5k) and 7-Methoxy-8-[5-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11 aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4]benzodiazepine-5-one (51). In still another embodiment quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5a-l exhibits an in vitro anticancer/antitumour activity against human cancer cell lines selected from the group consisting of lung, cervix, breast, colon, prostate and oral cell lines. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a process for preparation of pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula 5 of the drawing accompanying the specification where n = 1-3 which comprises reacting 1-(n-bromoalkyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone of formula 1 with 2S-A/-(4-hydroxy-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 2 in presence of CH3COCH3/K2CO3 in a period of 48 h isolating (2S)-A/-{4-[5-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]pentyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 by conventional methods, reducing the above nitro compounds of formula 3 with SnCl2.2H2O in presence of organic solvent up to a reflux temperature, isolating the (2S)-A/-{4-[5-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]pentyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 4 respectively by known methods, reacting the above said amino compound of formula 4 with known deprotecting agents in a conventional manner to give novel pyrrolo[2,1-c][1,4]benzodiazepine hybrids of formula 5, where 'n' are as stated above. The precursors, 1-(n-bromoalkyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone of formula 1 (Kamal, A.; Rao, K. R.; Sattur, P. B. Syn. Commun. 1980, 10, 799-804) and 2S-/V-(4-hydroxy-5-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethylthioacetal of formula 2 (Thurston, D. E.; Morris, S. J.; Hartley, J. A. Chem. Commun. 1996, 563-565) have been prepared by literature methods. Some representative compounds of formula 5 for the present inventions are given below 7-Methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one 7-Methoxy-8-[4-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)butyloxy]-(11 aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one 7-Methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one The process for the preparation of new pyrrolo[2,1-c][1,4]benzodiazepine hybrids is disclosed and claimed in our copending copatent application no. These new analogues of pyrrolo[2,1-c][1,4]benzodiazepine hybrids linked at C-8 position have shown promising DMA binding activity and efficient anticancer activity in various cell lines. The molecules synthesized are of immense biological significance with potential sequence selective DMA-binding property. This resulted in design and synthesis of new congeners as illustrated in Scheme-1, which comprise: 1. The ether linkage at C-8 position of DC-81 intermediates with 1-(n-bromoalkyl)-6- chloro-4-phenyl-1,2-dihydro-2-quinazolinone moiety. 2. Refluxing the reaction mixtures for 48 h. 3. Synthesis of C-8 linked PBD antitumour antibiotic hybrid imines. 4. Purification by column chromatography using different solvents like ethyl acetate, hexane, dichloromethane and methanol. The following examples are given by way of illustration and therefore should not be construed to the present limit of the scope of invention. Example 1 To a solution of (2S)-/V-(4-hydroxy-3-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal 2 (530 mg, 1.33 mmol) in dry acetone (20 ml_) was added anhydrous potassium carbonate (915 mg, 6.65 mmol) and 1-(3-bromopropyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone 1 (500 mg, 1.33 mmol). The reaction mixture was refluxed in an oil bath for 48 h and the reaction was monitored by TLC using ethyl acetate-hexane (4:6) as a solvent system. The potassium carbonate was then removed by suction filtration and the solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate: hexane (3:7) as a solvent system to obtain the pure product 3 (738 mg, 80% yield). 1H NMR (CDCI3) 8 1.16-1.34 (m, 6H), 1.58-2.14 (m, 6H), 2.28-2.41 (m, 3H), 2.60-2.93 (m, 4H), 3.14-3.28 (m, 2H), 3.98 (s, 3H), 4.17-4.21 (t, 2H), 4.48-4.50 (m, 1H), 6.78 (s, 1H), 7.38 (s, 1H), 7.55-7.65 (m, 3H), 7.72-7.78 (m, 3H), 7.82-7.84 (m, 2H). FABMS: 697 (M+H) 2S-A/-{4-[3-(6-Chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]propyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 (500 mg, 0.72 mmol) was dissolved in methanol (10 ml), SnCl2.2H2O (880 mg, 3.6 mmol) was added and refluxed until the TLC indicated the completion of the reaction. The methanol was evaporated by vacuum and the aqueous layer was then adjusted to pH 8 with 10% NaHCO3 solution and extracted with ethyl acetate (2x30 ml). The combined organic phase was dried over Na2SO4 and evaporated under vacuum to afford the crude amino diethylthioacetal 4 (450 mg, 95% yield), which was directly used in the next step. A solution of 2S-A/-{4-[3-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]propyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 4 (666 mg, 1 mmol), HgCI2 (613 mg, 2.26 mmol) and CaCO3 (240 mg, 2.46 mmol) in acetonitrile-water (4:1) was stirred slowly at room temperature for overnight until complete loss of starting material as indicated by the TLC. The clear yellow organic supernatant was extracted with ethyl acetate and washed with saturated 5% NaHC03 (20 mL), brine (20 mL) and the combined organic phase was dried over Na2S04. The organic layer was evaporated in vacuum to afford a white solid, which was first eluted on a column chromatography with ethyl acetate to remove mercuric salts, and then with dichloromethane: methanol (9:1) to obtain the pure product 5d (326 mg, 60% yield). 1H NMR (CDCI3) 8 1.85-2.26 (m, 6H), 2.33-2.46 (m, 4H), 3.52-3.93 (m, 1H), 3.98 (s, 3H), 4.11-4.25 (m, 2H), 6.96 (s, 1H), 7.31-7.42 (m, 1H), 7.53-7.61 (m, 3H), 7.68-7.76 (m, 3H), 7.81-7.84 (m, 2H), 7.94 (d, 1H, J= 5.2 Hz). FABMS: 543 (M+H) Example 2 To a solution of (2S)-A/-(4-hydroxy-3-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal 2 (512 mg, 1.28 mmol) in dry acetone (20 ml) was added anhydrous potassium carbonate (880 mg, 6.40 mmol) and 1-(4-bromobutyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone 1 (500 mg, 1.28 mmol). The reaction mixture was refluxed in an oil bath for 48 h and the reaction was monitored by TLC using ethyl acetate-hexane (2:8) as a solvent system. The potassium carbonate was then removed by suction filtration and the solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate: hexane (3:7) as a solvent system to obtain the pure product 3 (605 mg, 82% yield). 1H NMR (CDCI3) 8 1.18-1.38 (m, 8H), 1.59-2.18 (m, 6H), 2.26-2.42 (m, 3H), 2.53-2.90 (m, 4H), 3.18-3.29 (m, 2H), 3.96 (s, 3H), 4.18 (t, 2H), 4.54-4.55 (m, 1H), 6.73 (s, 1H), 7.4 (s, 1H), 7.6-7.68 (m, 3H), 7.75-7.85 (m, 3H), 7.98-8.0 (m, 2H). FABMS: 711 (M+H) 2S-A/-{4-[4-(6-Chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]butyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 (500 mg, 0.7 mmol) was dissolved in methanol (10 ml), SnCI2.2H2O (798 mg, 3.5 mmol) was added and refluxed until the TLC indicated the completion of the reaction. The methanol was evaporated by vacuum and the aqueous layer was then adjusted to pH 8 with 10% NaHC03 solution and extracted with ethyl acetate (2x30 ml_). The combined organic phase was dried over Na2SO4 and evaporated under vacuum to afford the crude amino diethylthioacetal 4 (355 mg, 95% yield), which was directly used in the next step. A solution of 2S-A/-{4-[4-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]butyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 4 (680 mg, 1 mmol), HgCI2 (613 mg, 2.26 mmol) and CaC03 (240 mg, 2.46 mmol) in acetonitrile- t water (4:1) was stirred slowly at room temperature for overnight until complete loss of starting material as indicated by the TLC. The clear yellow organic supernatant was extracted with saturated 5% NaHCOa (20 ml), brine (20 ml_) and the combined organic phase was dried over Na2SO4. The organic layer was evaporated in vacuum to afford a white solid, which was first eluted on a column chromatography with ethyl acetate to remove mercuric salts, and then with dichloromethane: methanol (9:1) to obtain the pure product 5e (306 mg, 55% yield). 1H NMR (CDCI3) 81.81-2.25 (m, 8H), 2.3-2.4 (m, 4H), 3.5-3.9 (m, 1H), 3.95 (s, 3H), 4.10-4.20 (m, 2H), 6.90 (s, 1H), 7.30-7.40 (m, 1H), 7.51-7.60 (m, 3H), 7.65-7.75 (m, 3H), 7.78-7.81 (m, 2H), 7.91 (d, 1H, J= 5.2 Hz). FABMS: 557 (M+H) Example 3 To a solution of (2S)-A/-(4-hydroxy)-3-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal 2 (400 mg, 1 mmol) in dry acetone (20 ml_) was added anhydrous potassium carbonate (690 mg, 5 mmol) and 1-(5-bromopentyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone 1 (405 mg, 1 mmol). The reaction mixture was refluxed in an oil bath for 48 h and the reaction was monitored by TLC using ethyl acetate-hexane (4:6) as a solvent system. The potassium carbonate was then removed by suction filtration and the solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethylacetate: hexane (3:7) as a solvent system to obtain the pure product 3 (617 mg, 82% yield). 1H NMR (CDCI3) 8 1.2-1.4 (m, 8H), 1.6-2.2 (m, 8H), 2.25-2.4 (m, 3H), 2.5-2.9 (m, 4H), 3.2-3.3 (m, 2H), 3.95 (s, 3H), 4.15 (t, 2H), 4.51-4.52 (m, 1H), 6.75 (s, 1H), 7.3 (s, 1H), 7.5-7.6 (m, 3H), 7.65-7.75 (m, 3H), 7.78-7.8 (m, 2H). FABMS: 725 (M+H) 2S-A/-{4-[5-(6-Chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]pentyl]oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 (500 mg, 0.69 mmol) was dissolved in methanol (10 ml), SnCl2.2H2O (786 mg, 3.45 mmol) was added and refluxed until the TLC indicated the completion of the reaction. The methanol was then evaporated in vacuum and the aqueous layer was then adjusted to pH 8 with 10% NaHCOa solution and extracted with ethyl acetate (60 ml). The combined organic phase was dried over NaaSCv and evaporated under vacuum to afford the crude amino diethyl thioacetal 4 (460 mg, 96% yield), which was directly used in the next step. A solution of 2S-A/-{4-[5-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]pentyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal 4 (694 mg, 1 mmol), HgCI2 (613 mg, 2.26 mmol) and CaCO3 (240 mg, 2.46 mmol) in acetonitrile-water (4:1) was stirred slowly at room temperature for overnight until complete loss of starting material as indicated by the TLC. The clear yellow organic supernatant was extracted with ethyl acetate and washed with saturated 5% NaHCOs (20 ml), brine (20 ml_) and the combined organic phase was dried over Na2SO4. The organic layer was evaporated in vacuum and to afford a white solid, which was first eluted on a column chromatography with ethyl acetate to remove mercuric salts, and then with dichloromethane: methanol (9:1) to obtain the pure product 5f (320 mg, 56% yield). 1H NMR (CDCI3) 6 1.73-2.15 (m, 10H), 2.25-2.38 (m, 4H), 3.45-3.87 (m, 1H), 3.93 (s, 3H), 4.05-4.10 (m, 2H), 6.83 (s, 1H), 7.24-7.32 (m, 1H), 7.43-7.58 (m, 3H), 7.63-7.72 (m, 3H), 7.72-7.79 (m, 2H), 7.87 (d, 1H, J= 5.2 Hz). FABMS: 571 (M+H) Cytotoxicity: The compounds 7-methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one and 7-methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one were evaluated for in vitro anticancer activity against nine human tumour cells derived from six cancer types (colon, prostate, oral, lung, cervix and breast cancer) as shown in (Table 1). Compounds 5d and 5f have been evaluated for their in vitro cytotoxicity in selected human cancer cell lines of colon (Colo205), lung (Hop-62), cervix (SiHa), prostate (DU145, PCS), oral (DWD, HT1080), and breast (MCF7, Zr-75-1) origin. A protocol of 48 h continuous drug exposure and an adriamycin (ADR) protein assay has been used to estimate cell viability or growth. The results are expressed as percent of cell growth determined relative to that of untreated control cells (Table 1). Compounds 5d and 5f » shows promising cytotoxicity against some cancer cell lines. Table 1. The percentage cell growth data for representative quinazolinone-PBD hybrids (Table 1 Removed) Compounds 5d and 5f exhibited less than 20% cell growth at |j,g/mL concentration in some cell lines. Compounds 5d and 5f suppress Colo205 cell growth by 92% and 85%, DU145 cell growth by 92% and 90%, DWD cell growth by 95%, Hop62 cell growth by 94% and 95%, HT1080 cell growth by 91% and 92%, MCF7 cell growth by 88% and 92% and PCS cell growth by 89% and 93%. They are suppressing the SiHa cell growth by 84% and Zr-25-1 cell growth by 92%. The DMA binding activity for these compounds has been examined by thermal denaturation studies using calf thymus (CT) DMA. Melting studies show that these compounds stabilize the thermal helix -» coil or melting stabilization (A7"m) for the CT-DNA duplex at pH 7.0, incubated at 37 °C, where PBD/DNA molar ratio is 1:5. In this assay these compounds elevate the helix melting temperature of CT-DNA in a range of 1.3-2.3 °C after incubation for 18 h at 37 °C. We claim 1. Novel quinazolinone linked pyrrolo [2,1-c][1,4,]benzodiazepine hybrid of general formula 5, (Formula Removed) wherein, R is an alkyl group selected from H, CI, F and CH3 and n = 1, 2, 3 or 4. 2. Novel quinalinone linked pyrrolo [2,1-c][1,4]benzodiazepine hybrid as claimed in claim 1 is represented by the group of the following compounds: 7-Methoxy-8-[3-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11 a-tetrahydro-5H-pyrrolo[2,1 -c][1,4] benzodiazepine-5-one(5a); 7 -Methoxy-8-[4-(6-H-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5b); 7-Methoxy-8-[5-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5c); 7-Methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one(5d); 7 -Methoxy-8-[4-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5e); 7-Methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5f); 7-Methoxy-8-[3-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one(5g); 7 -Methoxy-8-[4-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5h); 7-Methoxy-8-[5-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one(5i), 7-Methoxy-8-[3-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one(5j); 7 -Methoxy-8-[4-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5k) and 7-Methoxy-8-[5-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (51). 3. Novel quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid as claimed in claim 2, wherein the structural formula of the representative compounds are: (Structure Removed) 4 A process for the preparation of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of formula 5, (Formula Removed) wherein, R is alkyl group selected from H, CI, F and CH3 and n = 1, 2 or 3, the said process comprising the steps of: a) reacting (2S)-N-(4-hydroxy-3-methoxy-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 2 (Formula Removed) with 1-(3-bromo alkyl)-6-R-4-phenyl-1,2-dihydro-2-quinazolinone of formula 1, wherein R is selected from the group consisting of H, CI, F and CH3 and n = 1, 2 or 3, in an aprotic water miscible organic solvent, (Formula Removed) in the presence of anhydrous mild inorganic base, under refluxing temperature in an oil bath, for a period of about 48 hrs, followed by the removal of inorganic base by filtration and evaporating the organic solvent to obtain the resultant crude product and purifying it by known method to obtain the desired product of 2S-N-{4-[3-(6-R-4-phenyl-1,2-dihydro-2-quinazolinone)]alkyl]oxy-5-methoxy-2-nitrobenzoyl} pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3, (Formula Removed) b) reducing 2S-N-{4-[3-(6-R-4-phenyl-1,2-dihydro-2-quinazolinone)] alkyl] oxy-5-methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal of formula 3 with anhydrous tin chloride, in an alcohol, under reflux, followed by the evaporation of alcohol and adjusting the pH of the resultant product layer to about 8 by using a base, followed by extraction with ethyl acetate and washing the combined organic phase with brine solution and evaporating the solvent to obtain the desired 2S-N-{4-[3-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)]alkyl]oxy- 5-methoxy-2-aminobenzoyl} pyrroli dine -2-carboxaldehyde diethyl thioacetal of formula formula 4, wherein R is selected from the group consisting of H, CI, F and CH3 and n = 1, 2 or 3, (Formula Removed) c) reacting 2S-N-{4-[3-(6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone)] alkyl]oxy-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxaldehyde diethylthioacetal of formula 4 with mercurous chloride, in a mixture of water and organic solvent, in the presence of mild inorganic, under stirring, at a temperature of about 20-30°C, for a period of 8-12 hrs, followed by the extraction of yellow organic supernatant and washing with sodium bi carbonate and brine, respectively, and evaporating the organic layer, under reduced pressure to obtain the desired product of formula 5 5. A process as claimed in claim 4 wherein the mild organic base used in steps (a) and (b) is potassium carbonate. 6 A process as claimed in claim 4, wherein the aprotic organic solvent used in step (a) is acetone and acetonitrile. 7. A process as claimed in claim 4, wherein the organic solvent used in step (c) is acetonitrile. 8. A process as claimed in claim 4, wherein the alcohol used in step (b) is selected from methanol and ethanol. 9. A process as claimed in claim 4, wherein the compounds of formula 5 obtained are represented by a group of the following compounds: 7-Methoxy-8-[3-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one(5a); 7 -Methoxy-8-[4-(6-H-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5b); 7-Methoxy-8-[5-(6-H-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5c); 7-Methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one(5d); 7 -Methoxy-8-[4-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5e); 7-Methoxy-8-[5-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5f); 7-Methoxy-8-[3-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)propoxy]-(11 aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one(5g); 7 -Methoxy-8-[4-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5h); 7-Methoxy-8-[5-(6-floro-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (5i), 7-Methoxy-8-[3-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one(5j); 7 -Methoxy-8-[4-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)butyloxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine-5-one (5k) and 7-Methoxy-8-[5-(6-methyl-2-oxo-4-phenyl-1,2-dihydro-1 -quinazolinyl)pentyl oxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one(5l).

Documents:

1822-del-2006-abstract.pdf

1822-DEL-2006-Claims-(26-06-2012).pdf

1822-del-2006-claims.pdf

1822-del-2006-Correspondence Others-(01-06-2012).pdf

1822-DEL-2006-Correspondence Others-(26-06-2012).pdf

1822-del-2006-correspondence-others.pdf

1822-del-2006-description (complete).pdf

1822-del-2006-drawings.pdf

1822-del-2006-form-1.pdf

1822-del-2006-form-2.pdf

1822-del-2006-Form-3-(01-06-2012).pdf

1822-DEL-2006-Form-3-(26-06-2012).pdf

1822-del-2006-form-3.pdf

1822-del-2006-form-5.pdf

1822-DEL-2006-Petition-137-(26-06-2012).pdf

abstract.jpg